跳至主要内容
临床试验/ISRCTN27564683
ISRCTN27564683已完成未知

Eradicate Hepatitis C Virus: A pilot of treatment as prevention in active drug users

niversity of Dundee (UK)0 个研究点目标入组 94 人开始时间: 2012年11月22日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
94

研究概览

简要总结

2019 results in https://pubmed.ncbi.nlm.nih.gov/30422370/ (added 27/08/2020)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Male or female (age limit 18-70)
  • 2. Chronic HCV positive infection
  • 3. Genotype & PCR confirmed in addition to complying with all screening requirements
  • 4. If female, must have negative urine test results for pregnancy during initial screening period (for trial inclusion) & immediately prior to commencing study and agree to consider / commence adequate contraceptive cover (depot injection/ implanon rod)
  • 5. Current illicit IV drug use established through drug screening (oral swab / urine)
  • 6. Sign and date informed consent, agreeing to study and monitoring criteria

排除标准

  • 1. Aggressive or violent behaviour
  • 2. Inability to provide informed consent
  • 3. Features of decompensated liver failure
  • 4. Evidence of primary hepatocellular carcinoma
  • 5. Pregnancy, breast feeding, or pre-menopausal female not using effective contraception
  • 6. Patients with contraindications to use of interferon or ribavirin as congestive cardiac failure or known hypersensitivity to either product
  • 7. Previous treatment with Peginterferon alpha or Ribavirin or Telaprevir
  • 8. Participation in a drug study within the previous 30 days

研究者

发起方
niversity of Dundee (UK)

相似试验

Eradicate Hepatitis C Virus: a treatment to prevent... | 临床试验